Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Processa Pharmaceuticals Inc (NASDAQ: PCSA) closed at $0.25 down -7.16% from its previous closing price of $0.27. In other words, the price has decreased by -$7.16 from its previous closing price. On the day, 0.99 million shares were traded. PCSA stock price reached its highest trading level at $0.2829 during the session, while it also had its lowest trading level at $0.253.
Ratios:
For a deeper understanding of Processa Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.76 and its Current Ratio is at 3.76. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on April 25, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 27 ’25 when Yorke Justin W bought 12,400 shares for $0.80 per share. The transaction valued at 9,889 led to the insider holds 12,400 shares of the business.
Ng George K bought 87,200 shares of PCSA for $69,542 on Jan 27 ’25. The Chief Executive Officer now owns 87,200 shares after completing the transaction at $0.80 per share. On Jan 27 ’25, another insider, Young David, who serves as the Pres. Research & Development of the company, bought 124,500 shares for $0.80 each. As a result, the insider paid 99,289 and bolstered with 205,405 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCSA now has a Market Capitalization of 14330988 and an Enterprise Value of 8022568.
Stock Price History:
The Beta on a monthly basis for PCSA is 1.16, which has changed by -0.7413088 over the last 52 weeks, in comparison to a change of 0.1028198 over the same period for the S&P500. Over the past 52 weeks, PCSA has reached a high of $1.50, while it has fallen to a 52-week low of $0.15. The 50-Day Moving Average of the stock is -14.29%, while the 200-Day Moving Average is calculated to be -16.24%.
Shares Statistics:
For the past three months, PCSA has traded an average of 9.82M shares per day and 1605450 over the past ten days. A total of 52.86M shares are outstanding, with a floating share count of 49.24M. Insiders hold about 13.07% of the company’s shares, while institutions hold 3.14% stake in the company. Shares short for PCSA as of 1761868800 were 9049525 with a Short Ratio of 0.92, compared to 1759190400 on 2662436. Therefore, it implies a Short% of Shares Outstanding of 9049525 and a Short% of Float of 16.389999.
Earnings Estimates
The performance of Processa Pharmaceuticals Inc (PCSA) in the stock market is under the watchful eye of 1.0 analysts actively contributing to its current rating.
Analysts are recommending an EPS of between -$0.43 and -$0.43 for the fiscal current year, implying an average EPS of -$0.43. EPS for the following year is -$0.15, with 1.0 analysts recommending between -$0.15 and -$0.15.
